351 related articles for article (PubMed ID: 8616725)
21. Antiarrhythmic therapy in heart failure.
Eckardt L; Haverkamp W; Breithardt G
Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
[TBL] [Abstract][Full Text] [Related]
22. Treatment and prevention of sudden cardiac death--what have we learnt from randomised clinical trials?
Kam RM; Teo WS; Koh TH; Lim YL
Singapore Med J; 1999 Nov; 40(11):707-10. PubMed ID: 10709412
[TBL] [Abstract][Full Text] [Related]
23. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC; Morton BC; Green MS; Tang AS
Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
[TBL] [Abstract][Full Text] [Related]
24. An overview of antiarrhythmic drug management of electrical storm.
Kowey PR
Can J Cardiol; 1996 Apr; 12 Suppl B():3B-8B; discussion 27B-28B. PubMed ID: 8616726
[TBL] [Abstract][Full Text] [Related]
25. [Antiarrhythmic agents: current situation].
Bonhorst D
Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
Shantsila E; Watson T; Lip GY
Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
[TBL] [Abstract][Full Text] [Related]
27. Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs.
Oosterhoff P; Oros A; Vos MA
Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():73-8. PubMed ID: 17584687
[TBL] [Abstract][Full Text] [Related]
28. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials.
Yap YG; Duong T; Bland M; Malik M; Torp-Pedersen C; Køber L; Connolly SJ; Marchant B; Camm J
Eur Heart J; 2005 Jul; 26(14):1385-93. PubMed ID: 15914501
[TBL] [Abstract][Full Text] [Related]
29. Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial.
Jafri SM; Borzak S; Goldberger J; Gheorghiade M
Prog Cardiovasc Dis; 1998; 41(1):65-70. PubMed ID: 9717860
[TBL] [Abstract][Full Text] [Related]
30. [Anti-arrhythmic therapy and cardiac failure].
Cosnay P; Babuty D; Charniot JC; Fauchier L; Fauchier JP
Arch Mal Coeur Vaiss; 1995 Dec; 88 Spec No 5():35-41. PubMed ID: 8729298
[TBL] [Abstract][Full Text] [Related]
31. Amiodarone-associated "torsade de pointes". Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease.
Schrickel J; Bielik H; Yang A; Schwab JO; Shlevkov N; Schimpf R; Lüderitz B; Lewalter T
Z Kardiol; 2003 Oct; 92(10):889-92. PubMed ID: 14579055
[TBL] [Abstract][Full Text] [Related]
32. Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis.
Roden DM
Cardiovasc Res; 2005 Aug; 67(3):419-25. PubMed ID: 15936006
[TBL] [Abstract][Full Text] [Related]
33. Pro-arrhythmic effects of amiodarone and concomitant rate-control medication.
Schrickel JW; Schwab JO; Yang A; Bielik H; Bitzen A; Lüderitz B; Lewalter T
Europace; 2006 Jun; 8(6):403-7. PubMed ID: 16687421
[TBL] [Abstract][Full Text] [Related]
34. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
35. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
Brachmann J
Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
[TBL] [Abstract][Full Text] [Related]
36. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
Pratt CM; Luck JC; Mann DE; Wyndham CR
Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
[TBL] [Abstract][Full Text] [Related]
37. Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.
Yap YG; Camm AJ
Am J Cardiol; 1999 Nov; 84(9A):83R-89R. PubMed ID: 10568665
[TBL] [Abstract][Full Text] [Related]
38. [Anti-arrhythmia therapy after myocardial infarct: preliminary results of EMIAT and CAMIAT studies].
Kuck KH
Z Kardiol; 1996; 85 Suppl 6():107-13. PubMed ID: 9064953
[TBL] [Abstract][Full Text] [Related]
39. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
Vos MA; Crijns HJ
Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969
[TBL] [Abstract][Full Text] [Related]
40. [Arrhythmias and heart failure].
Amann FW; Candinas R
Ther Umsch; 1993 Jun; 50(6):419-24. PubMed ID: 8351673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
